DiaMedica Therapeutics (DMAC) EBT: 2017-2024
Historic EBT for DiaMedica Therapeutics (DMAC) over the last 8 years, with Dec 2024 value amounting to -$24.4 million.
- DiaMedica Therapeutics' EBT fell 26.69% to -$2.5 million in Q4 2019 from the same period last year, while for Dec 2019 it was -$10.6 million, marking a year-over-year decrease of 87.80%. This contributed to the annual value of -$24.4 million for FY2024, which is 26.25% down from last year.
- DiaMedica Therapeutics' EBT amounted to -$24.4 million in FY2024, which was down 26.25% from -$19.3 million recorded in FY2023.
- DiaMedica Therapeutics' EBT's 5-year high stood at -$12.3 million during FY2020, with a 5-year trough of -$24.4 million in FY2024.
- In the last 3 years, DiaMedica Therapeutics' EBT had a median value of -$19.3 million in 2023 and averaged -$19.1 million.
- Data for DiaMedica Therapeutics' EBT shows a maximum YoY tumbled of 41.69% (in 2023) over the last 5 years.
- Yearly analysis of 5 years shows DiaMedica Therapeutics' EBT stood at -$12.3 million in 2020, then fell by 10.59% to -$13.6 million in 2021, then dropped by 0.62% to -$13.6 million in 2022, then slumped by 41.69% to -$19.3 million in 2023, then decreased by 26.25% to -$24.4 million in 2024.